Q-omics provides the consensus-scored TSNAXIP1 profile across patient tissues and cancer cell-line models. TSNAXIP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TSNAXIP1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, TSNAXIP1 RNA expression shows 17,353 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KICH, and UVM as cancer lineages where TSNAXIP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSNAXIP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSNAXIP1 survival associations across molecular data types. TSNAXIP1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSNAXIP1 RNA expression–survival associations across cancer types. High TSNAXIP1 expression shows unfavorable associations in KIRC, LUAD and LUSC, but favorable associations in UCEC, KIRP and BLCA. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for TSNAXIP1 RNA expression.
This table summarizes TSNAXIP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TSNAXIP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSNAXIP1 shows lower tumor expression in KICH, THCA, LUSC and LUAD and higher tumor expression in KIRC and COAD. The KICH box plot shows higher TSNAXIP1 RNA expression in normal versus tumor tissue (log2 FC = −1.798, t-test p < 0.001).
This table shows molecular features associated with TSNAXIP1 in patient tissues and cancer cell lines. In patient samples, TSNAXIP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSNAXIP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
